Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.